Effect of Modified Erzhu Erchentang on Major Cardiovascular Risk Factors Caused by Type 2 Diabetes Mellitus with Phlegm Turbidity and Blood Stasis Syndrome / 中国实验方剂学杂志

ABSTRACT

Objective: To discuss the efficacy of Erzhu Erchentang on major cardiovascular risk factors caused by type 2 diabetes mellitus (T2DM)with phlegm turbidity and blood stasis syndrome, and its anti-inflammatory effect. Method: One hundred and forty-two patients were randomly divided into control group and observation group by random number table. Patients in control group got insulin or oral hypoglycemic drugs for controlling blood sugar, aspirin enteric-coated tablets, 100 mg/time, 1 time/day, telmisartan tablets, 40 mg/time, 1 time/day, atorvastatin, 10 mg/time, 1 time/day, and non-drug interventions. In addition to the therapy of control group, patients in observation group were also given modified Erzhu Erchentang, 1 dose/day, 5 times/week. The course of treatment was 24 weeks. And a 24-week follow-up was recorded. And levels of fasting blood glucose (FPG), 2 h postprandial blood glucose (2 hPG), glycosylated hemoglobin (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HLD-C) and low-density lipoprotein (LDL-C) were detected. And the occurrence of major cardiovascular events, cerebrovascular events and peripheral vascular events were recorded. Before and after treatment, levels of body mass index (BMI), carotid intima-media thickness (IMT), framingham risk (FRS) and waist-hip ratio (WHR) were assessed. And procalcitonin (PCT), homocysteine (Hcy), hypersensitive C-reactive protein (hs-CRP), cystatin C (CysC) and matrix metalloproteinase-9 (MMP-9) were measured. Result: After treatment, levels of 2 hPG, HbA1c, SBP, DBP, TC, TG, LDL-C, IMT and BMI in observation group were lower than those in control group (PPχ2=4.775, Pχ2=5.639, PZ=2.165, PPConclusion: In addition to the comprehensive therapy of conventional western medicine, modified Erzhu Erchentang can increase the reduce serum inflammatory factors and control the high risk factors of cardiovascular disease of patients with T2DM, so as to reduce the major cardiovascular events.